HK Stock Market Move | IMPACT THERAP-B (07630) opened nearly 15% higher; Senaparib receives European Commission approval for marketing, with active advancement of related global clinical development.
IMPACT THERAP-B (07630) opened nearly 15% higher. As of press time, it was up 14.96% at HK$10.72, with turnover of HK$3.3554 million.
IMPACT THERAP-B (07630) opened nearly 15% higher, up 14.96% as of press time at HK$10.72, with turnover of HK$3.3554 million.
On the news front, on November 17, IMPACT THERAP-B announced that its independently developed innovative drug Senaparib (China trade name: Paishuning, overseas trade name: Sepalna) has officially received a final decision from the European Commission (EC) approving it for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. This approval was made by the European Commission (EC) based on the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Senaparib has thus become the first China-originated PARP inhibitor approved in the EU for first-line maintenance treatment of the full population of advanced ovarian cancer, marking another breakthrough for a domestically developed targeted innovative drug for ovarian cancer in the European market.
Senaparib (Sepalna) is a novel, highly active PARP1/2 inhibitor independently developed by the Company. Its unique molecular structure ensures excellent target selectivity and a broad safety window. Senaparib capsules were approved by China's National Medical Products Administration in January 2025 for first-line maintenance treatment of adult patients with advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have achieved complete or partial response to platinum-based chemotherapy, and were subsequently included in the National Reimbursement Drug List in December 2025. The Company is actively advancing the global clinical and regulatory development of Senaparib. At the same time, the Company is also advancing the lifecycle management of Senaparib, exploring combination therapy opportunities, and expanding into multiple indications.
Related Articles

HK Stock Market Move | Hua Hong Grace Semiconductor (01347) rose over 10% in morning trading; Daiwa is bullish on the company's pricing power remaining strong through 2027.

HK Stock Market Move | XPENG-W (09868) rises over 5%; Q3 revenue and deliveries both hit record highs; Q4 total revenue expected to rise up to 42.9% year-on-year.

Orient: Liability repricing concludes + retail risk accelerated clearing; falling risk-free rates reinforce dividend value.
HK Stock Market Move | Hua Hong Grace Semiconductor (01347) rose over 10% in morning trading; Daiwa is bullish on the company's pricing power remaining strong through 2027.

HK Stock Market Move | XPENG-W (09868) rises over 5%; Q3 revenue and deliveries both hit record highs; Q4 total revenue expected to rise up to 42.9% year-on-year.

Orient: Liability repricing concludes + retail risk accelerated clearing; falling risk-free rates reinforce dividend value.






